Abiopharma

🔍 PYNNONEN BRETT D (Executive)

Company: VISTEON CORP (VC)

Report Date: 2026-03-15

Detailed Transactions and Holdings:

• Acquired 581 shares of Common Stock (Direct)
  Date: 2026-03-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 12,348.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 253 shares of Common Stock at $89.09 per share (Direct)
  Date: 2026-03-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 12,095.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 875 shares of Common Stock (Direct)
  Date: 2026-03-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 12,970.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 381 shares of Common Stock at $89.09 per share (Direct)
  Date: 2026-03-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 12,589.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 1,627 shares of Common Stock (Direct)
  Date: 2026-03-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 14,216.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 707 shares of Common Stock at $89.09 per share (Direct)
  Date: 2026-03-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 13,509.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 6 shares of Common Stock at $90.06 per share (Direct)
  Date: 2026-03-16 | Code: F | equity_swap_involved: 0 | shares_owned_after: 13,503.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 581 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-15 | Code: M | Expires: 2026-03-15 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F4
• Sold 875 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-15 | Code: M | Expires: 2027-03-15 | equity_swap_involved: 0 | shares_owned_after: 870.00 | transaction_form_type: 4 | Footnotes: F1, F1, F4
• Sold 1,627 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-15 | Code: M | Expires: 2028-03-15 | equity_swap_involved: 0 | shares_owned_after: 3,230.00 | transaction_form_type: 4 | Footnotes: F1, F1, F4

Footnotes:

• F1: Each Restricted Stock Unit, which is the economic equivalent of one share of Visteon common stock, automatically vested on March 15, 2026 and was converted and paid to me in common stock without any election or action on my part. The value of each share was based on the fair market value of Visteon common stock as of March 13, 2026, the next preceding trading day, and 22 of the shares reflect dividend equivalents paid in additional shares pursuant to the terms of the Visteon Corporation 2020 Incentive Plan.
• F2: These shares were withheld by Visteon to satisfy income tax withholding obligations arising in connection with the vesting of certain Restricted Stock Units. The value of each share was based on the fair market value of Visteon common stock as of March 13, 2026. the next preceding trading day.
• F3: The shares were withheld by Visteon to satisfy income tax withholding obligations arising in connection with the receipt of dividend equivalents pursuant to the terms of the Visteon Corporation 2020 Incentive Plan. The value of each share was based on the fair market value of Visteon common stock as of March 16, 2026.
• F4: Restricted Stock Units vest to the extent of 33% of the units granted on the following March 15th of each year after the date of grant. Each Restricted Stock Unit will be converted and distributed to me, without payment, in stock upon vesting and based upon the then current market value of a share of Visteon common stock, subject to tax withholding.